Search

Your search keyword '"Chéramy A"' showing total 476 results
Start Over Author "Chéramy A"
476 results on '"Chéramy A"'

3. Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease Patients

Author

Kautbally, Shakeel, Lepropre, Sophie, Onselaer, Marie-Blanche, Le Rigoleur, Astrid, Ginion, Audrey, De Meester de Ravenstein, Christophe, Ambroise, Jerome, Boudjeltia, Karim Z., Octave, Marie, Wéra, Odile, Hego, Alexandre, Pincemail, Joël, Cheramy-Bien, Jean-Paul, Huby, Thierry, Giera, Martin, Gerber, Bernhard, Pouleur, Anne-Catherine, Guigas, Bruno, Vanoverschelde, Jean-Louis, Kefer, Joelle, Bertrand, Luc, Oury, Cécile, Horman, Sandrine, and Beauloye, Christophe

Published
2019
Full Text
View/download PDF

5. Nanopackaging of Si(100)H Wafer for Atomic-Scale Investigations

Author

Sordes, Delphine, Thuaire, Aurélie, Reynaud, Patrick, Rauer, Caroline, Hartmann, Jean-Michel, Moriceau, Hubert, Rolland, Emmanuel, Kolmer, Marek, Szymonski, Marek, Durand, Corentin, Joachim, Christian, Chéramy, Séverine, Baillin, Xavier, Joachim, Christian, Series editor, and Kolmer, Marek, editor

Published
2017
Full Text
View/download PDF

7. DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission

Author

Fienberg, A. A., Hiroi, N., Mermelstein, P. G., Snyder, G. L., Nishi, A., Cheramy, A., O'Callaghan, J. P., Miller, D. B., Cole, D. G., Corbett, R., Haile, C. N., Cooper, D. C., Onn, S. P., Grace, A. A., Ouimet, C. C., White, F. J., Hyman, S. E., Surmeier, D. J., Nestler, E. J., and Greengard, P.

Published
1998

8. Chapter 24 - Life on land needs fresh water (SDG 15)

Author

Stokes, Gretchen L., Lynch, Abigail J., Smidt, Samuel J., Steel, E. Ashley, Dowd, Scott, Britton, J. Robert, Bai, Xue, Brophy Cerquera, Trista, Guerrero, Genaro, Cheramy, Jeantel, Koning, Aaron, Maghsood, Fatemeh Fadia, Piccillo, Ashley, and Schuppie, Grace

Published
2024
Full Text
View/download PDF

10. Silicon Technologies for Nanoscale Device Packaging

Author

Thuaire, Aurélie, Le Gac, Gaëlle, Audoit, Guillaume, Aussenac, François, Rauer, Caroline, Rolland, Emmanuel, Hartmann, Jean-Michel, Charvet, Anne-Marie, Moriceau, Hubert, Rivallin, Pierrette, Reynaud, Patrick, Cheramy, Severine, Sillon, Nicolas, Baillin, Xavier, Joachim, Christian, Series editor, Baillin, Xavier, editor, and Poupon, Gilles, editor

Published
2015
Full Text
View/download PDF

18. Nanopackaging of Si(100)H Wafer for Atomic-Scale Investigations

Author

Sordes, Delphine, primary, Thuaire, Aurélie, additional, Reynaud, Patrick, additional, Rauer, Caroline, additional, Hartmann, Jean-Michel, additional, Moriceau, Hubert, additional, Rolland, Emmanuel, additional, Kolmer, Marek, additional, Szymonski, Marek, additional, Durand, Corentin, additional, Joachim, Christian, additional, Chéramy, Séverine, additional, and Baillin, Xavier, additional

Published
2017
Full Text
View/download PDF

20. Oxidative Stress Status and its correlation with Redox Status as Measured By An Electrochemical (PAOT®) Methodology: A Pilot Study in Critical COVID-19 Pneumonia Survivors

Author

Pincemail, Joël, Rousseau, Anne-Françoise, Kaux, Jean-François, Cheramy-Bien, Jean-Paul, Bruyère, Christine, Prick, Jeanine, Stern, David, Mouna-Messaouda, Kaci, Maertens de Noordhout, Benoît, Albert, Adelin, Defraigne, Jean-Olivier, Misset, Benoît, Cavalier, Etienne, Charlier, Corinne, and Meziane, Smail

Published
2021
Full Text
View/download PDF

27. List of contributors

Author

Aggarwal, Aastha, Alam, Mohammad Ayaz, Bai, Xue, Bandyopadhyay, Somnath, Bhaduri, Anik, Bhattacharya, Prosun, Bhowmik, Tridip, Binh, Nguyen Thanh, Bouman Dentener, Alice, Britton, J. Robert, Brophy Cerquera, Trista, Caroline, Samberger, Cetrulo, Natália Molina, Cetrulo, Tiago, Cheramy, Jeantel, Coomar, Poulomee, Danert, Kerstin, Das, Kousik, Dash, Adya A., Dey, Uttiya, M. Dixit, Arun, Dowd, Scott, Duttagupta, Srimanti, Goncalves-Dias, Sylmara Lopes Francelino, Guerrero, Genaro, Gul, Iram, Hanley, Carol Diane, Healy, Adrian, Ijumulana, Julian, Jacobs-Mata, Inga, Javed, Asif, Kolusu, Seshagiri Rao, Koning, Aaron, Kreamer, David K., Lewis, Earl, Li, Bailing, Lynch, Abigail J., Maghsood, Fatemeh Fadia, Magombeyi, Manuel, Mani, Shyamala Krishna, Minh, Le Ba Nhat, Mitra, Bijon Kumer, Mitra, Priyanka, Mukherjee, Abhijit, Mukhopadhyay, Anwesha, Palrecha, Alka, Pavelic, Paul, Piccillo, Ashley, Polya, David, Puri, Shammy, Quan, Nguyen Hong, Rizwan, Wajiha, Rodell, Matthew, Sarkar, Soumyajit, Sathre, Roger, Schmitter, Petra, Schuppie, Grace, Schuster-Wallace, Corinne, Shamsudduha, Mohammad, Shaw, Rajib, Shridhar, Krithiga, Silva Pinto, Francisco, Smidt, Samuel J., Springer, Abraham E., Steel, E. Ashley, Stevens, Lawrence E., Stokes, Gretchen L., Sukhwani, Vibhas, Syme, Geoffrey John, Teixeira, Alexandre Lima de Figueiredo, Thi Ai Nhi, Truong, Tien, Le Van Thuy, Tu, Nguyen Minh, Villholth, Karen G., Vyas, Subroto, and Wu, Ruohan

Published
2024
Full Text
View/download PDF

32. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Author

Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Akerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson, and Rosaura Casas

Subjects
Medicine, Science
Abstract

A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the original 70 patients to investigate long-term cellular and humoral immune responses after GAD-alum-treatment. Peripheral blood mononuclear cells (PBMC) were stimulated in vitro with GAD(65). Frequencies of naïve, central and effector memory CD4+ and CD8+ T cells were measured, together with cytokine secretion, proliferation, gene expression and serum GAD(65) autoantibody (GADA) levels. We here show that GAD-alum-treated patients display increased memory T-cell frequencies and prompt T-cell activation upon in vitro stimulation with GAD(65), but not with control antigens, compared with placebo subjects. GAD(65)-induced T-cell activation was accompanied by secretion of T helper (Th) 1, Th2 and T regulatory cytokines and by induction of T-cell inhibitory pathways. Moreover, post-treatment serum GADA titres remained persistently increased in the GAD-alum arm, but did not inhibit GAD(65) enzymatic activity. In conclusion, memory T- and B-cell responses persist 4 years after GAD-alum-treatment. In parallel to a GAD(65)-induced T-cell activation, our results show induction of T-cell inhibitory pathways important for regulating the GAD(65) immunity.

Published
2011
Full Text
View/download PDF

42. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response

Author

Tavira Iglesias, Beatriz, Chéramy, Mikael, Axelsson Chéramy, Stina, Åkerman, Linda, Ludvigsson, Johnny, Casas, Rosaura, Tavira Iglesias, Beatriz, Chéramy, Mikael, Axelsson Chéramy, Stina, Åkerman, Linda, Ludvigsson, Johnny, and Casas, Rosaura

Abstract

Aims/hypothesis A European Phase III trial of GAD formulated with aluminiumhydroxide (GAD-alum) failed to reach its primary endpoint (preservation of stimulated C-peptide secretion from baseline to 15 months in type 1 diabetes patients), but subgroup analysis showed a clinical effect when participants from Nordic countries were excluded, raising concern as to whether the mass vaccination of the Swedish and Finnish populations with the Pandemrix influenza vaccine could have influenced the study outcomes. In the current study, we aimed to assess whether Pandemrix vaccination affects the specific immune responses induced by GAD-alum and the C-peptide response. Methods In this secondary analysis, we analysed data acquired from the Swedish participants in the Phase III GAD-alum trial who received subcutaneous GAD-alum vaccination (two doses, n = 43; four doses, n = 46) or placebo (n = 48). GAD autoantibodies (GADA) and H1N1 autoantibodies, GAD(65)-induced cytokine secretion and change in fasting and stimulated C-peptide levels from baseline to 15 months were analysed with respect to the relative time between H1N1 vaccination and the first injection of GAD-alum. Results GADA levels at 15 months were associated with the relative time between GAD-alum and Pandemrix administration in participants who received two doses of the GAD-alum vaccine (p = 0.015, r = 0.4). Both in participants treated with two doses and four doses of GAD-alum, GADA levels were higher when the relative time between vaccines was amp;gt;= 210 days (p amp;lt; 0.05). In the group that received two doses of GAD-alum, levels of several GAD(65)-induced cytokines were higher in participants who received the H1N1 vaccination and the first GADalum injection at least 150 days apart, and the change in fasting and stimulated C-peptide at 15 months was associated with the relative time between vaccines. Neither of these effects were observed in individuals who received four doses of GAD-alum. Conclusions/interpreta, Funding Agencies|JDRF [17-2011-249]; Swedish Research Council [K2008-55x-20,652-01-3]; Swedish Child Diabetes Foundation (Barndiabetesfonden); Medical Research Council of Southeast Sweden; Diamyd Medical

Published
2017
Full Text
View/download PDF

46. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months

Author

Mikael Pihl, Stina Axelsson, Johnny Ludvigsson, Rosaura Casas, Mikael Chéramy, and Linda Åkerman

Subjects
medicine.medical_specialty, Type 1 diabetes, C-peptide, business.industry, Endocrinology, Diabetes and Metabolism, Insulin, medicine.medical_treatment, Area under the curve, Placebo, medicine.disease, Surgery, chemistry.chemical_compound, Subcutaneous injection, Endocrinology, chemistry, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, Adverse effect, business
Abstract

Background This study aimed to analyse data from two different studies (phase II and phase III) regarding the safety and efficacy of treatment with alum formulated glutamic acid decarboxylase GAD65 (GAD-alum) at 30 months after administration to children and adolescents with type 1 diabetes. Methods The phase II trial was a double-blind, randomised placebo-controlled study, including 70 children and adolescents who were followed for 30 months. Participants received a subcutaneous injection of either 20 µg of GAD-alum or placebo at baseline and 1 month later. During a subsequent larger European phase III trial including three treatment arms, participants received two or four subcutaneous injections of either 20 µg of GAD-alum and/or placebo at baseline, 1, 3 and 9 months. The phase III trial was prematurely interrupted at 15 months, but of the 148 Swedish patients, a majority completed the 21 months follow-up, and 45 patients completed the trial at 30 months. Both studies included GAD65 auto-antibodies-positive patients with fasting C-peptide ≥0.10 nmol/l. We have now combined the results of these two trials. Results There were no treatment related adverse events. In patients treated with 2 GAD-alum doses, stimulated C-peptide area under the curve had decreased significantly less (9 m: p 0.2 nmol/L (p

Published
2014
Full Text
View/download PDF

48. Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial

Author

Stina Axelsson, Linda Åkerman, Rosaura Casas, Mikael Chéramy, Johnny Ludvigsson, and Mikael Pihl

Subjects
Adult, Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Glutamate decarboxylase, Immunoglobulin G, chemistry.chemical_compound, Immune system, Diabetes mellitus, Internal Medicine, Medicine, Humans, Insulin, Original Research, Autoantibodies, Advanced and Specialized Nursing, Type 1 diabetes, Immunity, Cellular, biology, business.industry, Alum, Glutamate Decarboxylase, Autoantibody, Klinisk medicin, Clinical Care/Education/Nutrition/Psychosocial Research, Middle Aged, medicine.disease, Immunity, Humoral, Diabetes Mellitus, Type 1, chemistry, Immunology, biology.protein, Leukocytes, Mononuclear, Alum Compounds, Female, Clinical Medicine, business
Abstract

OBJECTIVE GAD formulated in aluminum hydroxide (GAD-alum) has previously been shown to induce preservation of residual insulin secretion in recent-onset type 1 diabetes, but recent phase II and III GAD-alum trials failed to reach primary outcomes. The European phase III study was therefore closed after 15 months, and only a minority of patients completed the 30 months of follow-up. RESEARCH DESIGN AND METHODS This study aimed to characterize cellular and humoral responses in the Swedish patients (n = 148) participating in the phase III trial, receiving four (4D) or two (2D) GAD-alum doses or placebo. Serum GAD65 antibody (GADA) levels, GADA IgG1–4 subclass distribution, cytokine secretion, and proliferative responses in peripheral blood mononuclear cells (PBMCs) were analyzed. RESULTS The GAD65-induced cytokine profile tended to switch toward a predominant Th2-associated profile over time both in the 2D and 4D group. The groups also displayed increased GADA levels and PBMC proliferation compared with placebo, whereas GADA IgG subclass distribution changed in 4D patients. CONCLUSIONS Both 2D and 4D patients displayed GAD65-specifc cellular and humoral effects after GAD-alum treatment, but at different time points and magnitudes. No specific immune markers could be associated with treatment efficacy.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results